Viking Therapeutics Inc (NASDAQ:VKTX) gapped up prior to trading on Thursday . The stock had previously closed at $7.80, but opened at $8.00. Viking Therapeutics shares last traded at $8.28, with a volume of 2185992 shares changing hands.

Several analysts recently weighed in on VKTX shares. Maxim Group reaffirmed a “buy” rating and issued a $28.00 target price on shares of Viking Therapeutics in a report on Thursday, November 8th. Roth Capital boosted their target price on shares of Viking Therapeutics from $13.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 19th. BidaskClub lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 3rd. William Blair restated a “market perform” rating on shares of Viking Therapeutics in a research report on Monday, October 1st. Finally, Raymond James upgraded shares of Viking Therapeutics from an “outperform” rating to a “strong-buy” rating and set a $43.00 target price on the stock in a research report on Monday, November 19th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.29.

The company has a market capitalization of $608.84 million, a PE ratio of -10.48 and a beta of 3.01.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. As a group, analysts anticipate that Viking Therapeutics Inc will post -0.43 EPS for the current year.

A number of hedge funds have recently made changes to their positions in VKTX. FMR LLC acquired a new position in Viking Therapeutics in the 3rd quarter valued at about $125,858,000. BlackRock Inc. grew its holdings in Viking Therapeutics by 681.0% in the 2nd quarter. BlackRock Inc. now owns 2,938,645 shares of the biotechnology company’s stock valued at $27,888,000 after buying an additional 2,562,356 shares during the period. Jennison Associates LLC purchased a new stake in Viking Therapeutics in the 3rd quarter valued at about $9,501,000. Vanguard Group Inc. grew its holdings in Viking Therapeutics by 21.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,877,287 shares of the biotechnology company’s stock valued at $50,123,000 after buying an additional 508,097 shares during the period. Finally, Vanguard Group Inc grew its holdings in Viking Therapeutics by 21.4% in the 3rd quarter. Vanguard Group Inc now owns 2,877,287 shares of the biotechnology company’s stock valued at $50,123,000 after buying an additional 508,097 shares during the period. 59.79% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/viking-therapeutics-vktx-shares-gap-up-to-8-00/2753539.html.

Viking Therapeutics Company Profile (NASDAQ:VKTX)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

See Also: How Short Selling Works

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.